These advancementscollectively enhance the accuracy of cancer diagnosis and longitudinalmonitoring, offering a robust alternative to existing techniques.While validated using established biomarkers (EpCAM, miRNA-21 andmiRNA-23a) for colorectal cancer detection, the platform’smodular architecture that are characterized by substitutable aptamersfor biomarker-specific EV capture, customizable CRISPR probes fortarget RNA detection, and adjustable gold nanoarray, positions itas a broadly applicable and versatile diagnostic tool. Here, EPCAM is linked to cancer.